Clinical Trial Update: A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases [Phase 3]

View source ↗

Summary

Phase III results for D961H at 10 mg and 20 mg in Japanese pediatric patients with gastrointestinal acid-related diseases have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anastomotic Ulcer
• Duodenal Ulcer
• Gastric Ulcer
• Non-erosive Reflux Disease
• Reflux Esophagitis
• Zollinger-ellison Syndrome

Drugs mentioned

• D961H 10 mg
• D961H 20 mg

Snippet

Sponsor: AstraZeneca | Conditions: Gastric Ulcer (GU), Duodenal Ulcer (DU) | Phase 3 | Status: COMPLETED | Results posted: 2017-01-19